# Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

> **NCT00167518** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Sydney** · enrollment: 70 (—)

## Conditions studied

- Diabetic Macular Oedema

## Interventions

- **DRUG:** Triamcinolone acetate

## Key facts

- **NCT ID:** NCT00167518
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 70 (—)
- **Last updated:** 2005-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00167518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00167518, "Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00167518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*